Final Program Collaborators

December 2-4, 2014 Shaw Centre (formerly the Ottawa Convention Centre)

FINAL PROGRAM COLLABORATORS

The Canadian Immunization Conference is pleased to host CIC 2014 in collaboration with:

Canadian Association for Immunization Research and Evaluation (CAIRE) CAIRE is a unique professional organization of more than 140 Canadian researchers dedicated to building the scientific foundation for optimal immunization programs. Members are involved in vaccine and program development, program evaluation, social science of vaccine use and training of the next generation of vaccinologists. CAIRE’s mission is to encourage and enhance vaccinology research so Canadians have timely access to new and improved vaccines and optimal programs. CAIRE promotes collaboration and networking amongst the vaccinology disciplines to ensure that suitable expertise exists to maintain Canada as a world leader in high quality vaccinology research.

Canadian Paediatric Society (CPS) The CPS is the national association of paediatricians, committed to working together to advance the health of children and youth by nurturing excellence in health care, advocacy, education, research and support of its membership. As a voluntary professional association, the CPS represents more than 3,000 paediatricians, paediatric subspecialists, paediatric residents, and other people who work with and care for children and youth.

Canadian Public Health Association (CPHA) Founded in 1910, CPHA is the independent voice for public health in Canada with links to the international community. As the only Canadian non-governmental organization focused exclusively on public health, CPHA is uniquely positioned to advise decision-makers about public health system reform and to guide initiatives to help safeguard the personal and community health of Canadians and people around the world. CPHA’s mission is to enhance the health of people in Canada and to contribute to a healthier and more equitable world.

Public Health Agency of Canada The Agency is responsible for promoting and protecting the health of Canadians through leadership, partnership, innovation and action in public health. Through our research, programs and services, our goals are to bring about healthier Canadians, reduced health disparities, and a stronger capacity to deliver on and support public health activities.

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM ABOUT CIC

One hundred years ago, infectious diseases were the leading cause of death worldwide. In Canada, they now cause less than 5% of all deaths – largely thanks to vaccines.

From December 2-4, 2014, public health practitioners, health care providers, vaccine providers, researchers, immunization policy-makers and program managers, vaccine manufacturers, academics, students and other stakeholders who contribute to Canada’s vaccination system will gather in Ottawa, Ontario at the 2014 Canadian Immunization Conference to demonstrate their commitment to immunization as an important public health measure.

Immunization protects individuals and communities by preventing the spread of disease. As more people are immunized, the disease risk for everyone is reduced. Immunization has probably saved more lives in Canada in the last 50 years than any other health intervention. Immunization is the single most cost-effective health investment, making it a cornerstone in the effort to promote health.

The ongoing occurrence of vaccine-preventable disease outbreaks makes CIC 2014 an important venue to discuss the recurrence and emergence of infectious diseases that are posing challenges for public health at all levels. Critical to our degree of preparedness are an ability to continue to develop and improve vaccines, strengthen public health surveillance systems, and support timely and practice-relevant immunization program research, as well as an encouraging of evidence-based and ethical policy and practice measures to help us better control infectious diseases and improve public confidence in vaccines.

CIC 2014 will bring together non-governmental organizations, vaccine manufacturers, provincial and territorial immunization policy and program planners, as well as professionals from the many disciplines involved in the immunization field.

Conference Goals CIC 2014 will provide: • a dynamic setting to profile new research, successful strategies and best practices, to inspire innovation and to encourage further collaborations; • a venue for new and returning vaccination stakeholders to collaborate, innovate and help shape the future of Canada’s vaccination research, policies and programs; and • an inclusive networking and knowledge exchange forum at the national level to identify, discuss and troubleshoot current vaccine- and immunization-related issues across a range of disciplines and sectors.

Learning Objectives Having attended CIC 2014, delegates will be better prepared to: • utilize effective evidence-based programs and best clinical practices as well as policy approaches; • describe vaccine related research and identify colleagues and partners to develop initiatives; and • identify vaccination-related challenges and solutions, trends, emerging issues and evidence gaps.

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 1 PROGRAM-AT-A-GLANCE

TIME TUESDAY 2 DECEMBER WEDNESDAY 3 DECEMBER THURSDAY 4 DECEMBER

7:00

7:30 Co-Developed Learning Co-Developed Learning Activities Activities 8:00

8:30 Opening Session 9:00

9:30 Plenary I Plenary II Plenary III 10:00

10:30 Break in Exhibit Hall Break in Exhibit Hall Break in Exhibit Hall 11:00

11:30 Concurrent Sessions Concurrent Sessions Concurrent Sessions 12:00

12:30 Lunch 13:00 Lunch in Exhibit Hall + Lunch in Exhibit Hall + 13:30 Dedicated Poster-viewing Dedicated Poster-viewing Plenary IV Time Time 14:00 Closing 14:30

15:00 Concurrent Sessions Concurrent Sessions 15:30

16:00 Welcome Reception Networking Event 16:30 in Exhibit Hall in Exhibit Hall

17:00

2 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM GENERAL INFORMATION

Registration and Information Desk Registration will be available on the Level 2 of the Shaw Centre as follows: • Monday, December 1 12:00-17:00 • Tuesday, December 2 07:00-17:00 #cic2014 • Wednesday, December 3 07:00-17:00 @cic2014cci • Thursday, December 4 07:00-12:00

Badge Identification Name badges are colour coded and allow admission to all program and social events. Please wear your badge at all times. Participants are identified as follows: Delegates White Committee Members Blue Sponsor Light Green Exhibitor Dark Green Invited Speaker Purple Media Beige Volunteer Yellow

Accreditation This event has been approved by the Canadian Paediatric Society for a maximum of 18.5 credit hours as an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada. If you are a member of the College of Family Physicians of Canada please contact [email protected] or 1-800-387- 6197, ext. 243 or 204 for information on claiming credits for this event.

Co-developed Accredited Learning Activities Program The Conference program will include Co-developed Accredited Learning Activities. Each of these sessions will be accredited by the Canadian Paediatric Society (CPS) or the Association of Medical Microbiology and Infectious Disease Canada (AMMI) and must comply with the accreditation guidelines and procedures of these organizations.

Simultaneous Interpretation Simultaneous interpretation will be offered for all sessions. Headsets will be available to delegates at the registration desk. Identification will be required to pick up your headset. Please return the headset to the registration desk at the end of each day.

Speaker Ready Room – Room 211 The Speaker Ready Room, located in Room 211 at the Shaw Centre, is set aside as a quiet room for reviewing of your presentation material or for any last-minute presentation changes. Speakers are asked to check in with the onsite Presentation Technician at least 2 hours prior to your presentation. The computers in the Speaker Ready Room are configured with the same hardware and software as those in the meeting rooms. We encourage you to preview your presentation and ensure graphics, text and media files display as needed. The Speaker Ready Room will be open: • Monday, December 1 12:00-17:00 • Tuesday, December 2 08:00-16:00 • Wednesday, December 3 08:00-16:00 • Thursday, December 4 08:00-10:00

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 3 GENERAL INFORMATION

Disclosure of Conflict of Interest To ensure balance, independence, objectivity and scientific rigor, all presenters have been asked to inform audience members of any possible affiliations or financial interests that may have a direct bearing on the subject matter of the presentation. Such conflicts could include, but are not limited to: employment, ownership of stock, involvement with industry advisory boards, or participation in industry-sponsored clinical research. Other potential areas of real or perceived conflict of interest could include receiving honoraria or expenses from a commercial organization in relation to the presentation.

Students Presenters CIC and its partners are committed to building capacity among the next generation of leaders. Look for the student icon in the program to highlight presentations that are being given by students.

Photo/Video Reproduction When you registered for CIC 2014, you agreed to allow CPHA to: • take photographs or video recordings of you at this event • use these images in any way for educational or promotional purposes afterwards without notifying you, paying you, or asking for your consent or approval.

Exhibit Hall – Canada Hall 2 & 3 Interact with 30 exhibitors from across the country and meet fellow attendees as you mingle, network and make lasting connections.

Cyber Café – Parliament Foyer To access email while in Ottawa, a Cyber Café is available in the Parliament Foyer. In consideration of others, please limit your time if others are waiting.

Scent-free Environment For the comfort of all delegates, we ask your cooperation in refraining from wearing scented products while attending the conference.

Cell Phones Please turn off your cell phone upon entering session rooms.

Green Initiatives The Shaw Centre is a strong advocate for environmental respect, conservation, and sustainable living. This centre is a green building demonstration to visitors as well as a visible landmark for sustainability in Ottawa.

The Shaw Centre is a LEED Gold certified building. LEED (Leadership in Energy and Environmental Design) is a green building rating system administered by the non-profit Canada Green Building Council. The Shaw Centre has utilized cutting-edge environmentally sound technology in six categories: Sustainable Sites, Water Efficiency, Energy & Atmosphere, Materials & Resources, Indoor Environment, and Innovation & Design.

WIRELESS NETWORK: CIC2014 PASSWORD: VACCINE2014

4 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM EXHIBIT HALL

ORGANIZATION Booth #

AbbVie 27

AstraZeneca 21

BIOTECanada 26

Canadian Paediatric Society 16

CardioMed Supplies Inc. 9

Canadian Public Health Association 15

Government of Canada 20

GSK 25

Immunize Canada 14

Intern. Centre for Infectious Disease 24

Medicago 7

Merck Canada Inc. 8

Novartis 3 - 6

Pfizer 10 - 13

Public Health Ontario 2

Sanofi Pasteur 22 & 23

Society of Obstetricians & Gynaecologists 28

TempStable Refrigeration 29

Vaccines411 1

VeriCor, LLC 17 #cic2014 @cic2014cci

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 5 U R IMMUNIZED

URIMMUNIZED.CA

We believe the future is for all to share in. That is why we are committed to advancing vaccine technologies that aim to equip and protect people of all

TM ages and at all stages of life.

Helping support your efforts towards patient care.

Find out more at URimmunized.ca

URIMMUNIZED.CA

We believe the future is for all to share in. That is why we are committed to advancing vaccine technologies that aim to equip and protect people of all

TM ages and at all stages of life.

Helping support your efforts towards patient care.

Find out more at URimmunized.ca

08:30 – 10:30 Canada Hall 1 (Level 3) OPENING CEREMONY AND PLENARY I

Moderator • Ian Culbert, Executive Director, Canadian Public Health Association Traditional First Nation’s Welcome • Albert Dumont, Elder, Kitigan Zibi Anishinabeg First Nation Welcome Remarks • Gregory Taylor, Chief Public Health Officer, Public Health Agency of Canada • John Spika, Director General, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada • David Scheifele, Chair, Canadian Association for Immunization Research and Evaluation • Marie Adèle Davis, Executive Director, Canadian Paediatric Society • Andrew Casey, Chief Executive Officer, BIOTECanada

2014 National Immunization Poster Contest Award The Public Health Agency of Canada and Immunize Canada are pleased to present the 2014 National Immunization Poster Contest. Grade 6 students from across Canada were invited to create posters expressing their ideas about immunization and healthy children. One national grand prize winner and one national runner-up were chosen, and one winner was chosen from each participating province and territory. All winning posters will be displayed at CIC 2014 and on the Immunize Canada website: http://immunize.ca/en/events/ imm-poster-contest.aspx. The calendar of winning posters is available at the registration desk or the Immunize Canada booth (# 14). Presented by: • Shelly McNeil, Vice-chair, Immunize Canada; Professor of Medicine, Infectious Disease Consultant, Queen Elizabeth II Health Sciences Centre • Bonnie Henry, Deputy Provincial Health Officer, British Columbia

Distinguished Lecture in Canadian Immunization Established in 2008, the Distinguished Lecture in Canadian Immunization Award is granted by the Awards Committee of the Canadian Immunization Conference every two years. This tribute recognizes outstanding career achievement in the field of Canadian immunization.

8 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM TUESDAY, DECEMBER 2

Scott Halperin, 2014 Distinguished Lecture in Canadian Immunization Recipient Dr. Halperin has been a leader in the field of immunization over his career. As an infectious diseases consultant he has cared for patients with vaccine preventable diseases. He has done pivotal research work that goes from bench to bedside. He continues to lead national networks such as the Immunization Monitoring Program Active (IMPACT), the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) and the Canadian Immunization Research Network (CIRN) to generate knowledge around vaccine preventable disease surveillance, immunization program practices and knowledge translation. He has taught and supervised students at a variety of different levels of training, and by doing so has contributed to the future of vaccine research in Canada.

Plenary I: Pregnancy – A time to vaccinate Vaccination during pregnancy has the potential to provide benefit to the woman, the fetus, and the newborn infant. While tetanus vaccination during pregnancy has been instrumental during the last 30 years in eliminating neonatal tetanus throughout the developing world, routine tetanus vaccination during pregnancy has lagged behind in more developed countries. Pregnant women are now one of the highest priorities for influenza vaccination globally, and pertussis vaccination during pregnancy has been recommended as a response to high rates of neonatal pertussis deaths. As new vaccines for use in pregnancy are in development for group B streptococcus and for respiratory syncytial virus and with increasing evidence of the safety and effectiveness of maternal immunization, a pregnancy vaccine platform should become as accepted and routine as infant immunization. However, the path to achieve this goal needs to be carefully planned and implemented. Learning Objectives: • Explore the benefits of vaccination during pregnancy. • Describe the evidence regarding the safety and effectiveness of maternal immunization. • Identify the need for a schedule and platform for routine immunization during pregnancy. Speaker: Scott Halperin, Medical Director, Clinical Research and Vaccine Challenge Unit, Canadian Centre for Vaccinology, & Professor, Department of Pediatrics, Dalhousie University Session Chair: David Scheifele, Senior Clinician Scientist, Director, Vaccine Evaluation Centre, Child and Family Research Institute & Professor, Division of Infectious and Immunological Diseases, University of British Columbia

10:30 – 11:00 Canada Hall 2 & 3 (Level 3) REFRESHMENT BREAK

10:30 – 17:30 Canada Hall 2 & 3 (Level 3) EXHIBIT PROGRAM

#cic2014 @cic2014cci

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 9 TUESDAY, DECEMBER 2

CONCURRENT SESSIONS 11:00 – 12:30

Monitoring & Surveillance Oral Abstract Session 1 Room 202 Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec – Geneviève Deceunick Frailty in relation to influenza burden of disease and serious outcomes: A report from PCIRN Serious Outcomes Surveillance (SOS) Network – Ellen MacDonald Seasonal influenza vaccine effectiveness in adults working in hospitals: 2010/11 through 2013/14 –Brenda Coleman The Canadian National Vaccine Safety (CANVAS): Active surveillance for adverse events following immunization with seasonal influenza vaccines in 2013 and 2014 – Julie Bettinger End-of-season estimates of 2013 and 2014 influenza vaccine effectiveness from the Canadian Sentinel Physician Surveillance Network (SPSN) – Danuta Skowronski Oral Abstract Session 2 Room 204 HPV vaccination program impact on genital warts in Quebec – Marc Steben 2-year-old immunization coverage in Fraser Health, British Columbia: Beyond up-to-date status – Emily Newhouse Decreases in hospitalizations: Effect of rotavirus vaccine programs – Nicole Le Saux Cardiac complications of community-acquired pneumonia among hospitalized Canadian adults: A PCIRN Serious Outcomes Surveillance (SOS) Network Study – George Worthen Who’s at risk? The incidence of invasive pneumococcal disease in Ontario – Shelley Deeks

Vaccine Research & Development Room 206 Vaccinating to protect mother and child: Is there a made-in-Canada strategy? A baby gets disease immunity from the mother during pregnancy and this immunity will protect the baby from some diseases during the first few months of life. In this session we will provide an overview of the rationale for immunizing pregnant women against infectious diseases, consider issues that shape how information about immunization is communicated from health care workers to pregnant women, and in an interactive component, discuss possible strategies to improve pregnant women’s access to recommended vaccines in Canada. Learning Objectives: • Describe the evidence for immunization of pregnant women. • Describe evidence-based strategies for conveying information appropriately, including in emotional circumstances. • Apply knowledge about maternal immunization in the design of immunization programs and clinical practice in order to prevent maternal and infant infection and infection-related complications. Speakers: Vicki LeBlanc, Associate Director, The Wilson Centre for Research in Education, University of Toronto Mark Yudin, Associate Professor, University of Toronto & Obstetrics, Gynecology, & Reproductive Infectious Diseases, St. Michael’s Hospital Session Chair: Joanne Langley, Professor of Pediatrics, Faculty of Medicine, Dalhousie University

10 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 11:00 - 12:30 • TUESDAY, DECEMBER 2

Policy-making Room 208 Vaccine decision: Beyond the science Economic perspectives (value for money) and disease dynamics (indirect effects and changing epidemiology) influence the decision to adopt a new vaccine into a vaccination program. Vaccines, however, are different from other health technologies and pharmaceuticals. In addition to the economic and disease dynamic considerations, there are also political dimensions, ethics and advocacy that enter into the decision-making process. This session will review the complexities – beyond the science – that influence the adoption of new vaccines into vaccination programs. Learning Objectives: • Identify the complexities associated with vaccine decision making, including economics, disease dynamics, politics and ethics. • Describe how economics and disease dynamics may result in complementary or conflicting conclusions. • Explain how ethical dimensions may impact both political and economic outcomes. Speakers: David Fisman, Professor of Epidemiology, Dalla Lana School of Public Health, University of Toronto Bonnie Henry, Deputy Provincial Health Officer, British Columbia Eric Wasylenko, Ethics Advisor, Alberta Advisory Committee on Immunizations, Alberta Health Session Chair: Caroline Quach, Pediatric Infectious Disease Consultant and Medical Microbiologist, Infection Control and Prevention, The Montreal Children’s Hospital, McGill University

Programs Room 210 Immunization coverage in Canada Immunization coverage provides a glimpse into vaccine uptake levels in Canada and predicts whether populations are adequately protected from vaccine-preventable diseases. This session will present the most recent approaches to validating coverage data, explore differences in uptake rates between regions and discuss coverage trends and forecasts. Learning Objectives: • Identify trends in immunization coverage in Canada, including geographic differences, trends over time, and specific uptake. • Describe methods used for validating coverage data from registries and exploring factors associated with coverage. Speakers: Samara David, Surveillance Epidemiologist, BC Centre for Disease Control Douglas Dover, Senior Methodologist, Surveillance & Assessment Branch, Alberta Health Julie Laroche, Manager, Immunization Assessment and Information, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada Sarah Wilson, Medical Epidemiologist, Immunization and Vaccine-Preventable Diseases, Public Health Ontario Session Chair: Monika Naus, Medical Director, Immunization Programs and Vaccine Preventable Diseases, BC Centre for Disease Control & Associate Professor, School of Population and Public Health, University of British Columbia

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 11 TUESDAY, DECEMBER 2 • 11:00 - 12:30

Practice Room 215 First Nations vaccination program: Best practices through innovation and partnership To overcome the challenges of engaging First Nations communities in vaccination coverage, researchers, practitioners, and decision- and policy-makers need to be able to communicate effectively and identify solutions that reflect these communities’ aims and values. This session will provide an overview of successful strategies used to increase coverage in First Nations communities. The importance of distinguishing the particular needs of certain populations in Canada will be explored and the issues faced during the planning and implementation phases of vaccine programs will be discussed. This session will feature best practices that utilize innovation, partnership and integration to define and support vaccination coverage in First Nations communities. Learning Objectives: • Identify successful strategies used to increase vaccination coverage. • Distinguish the particular needs of certain populations in Canada that should be considered in the planning and implementation of vaccine programs. • Identify best practices in record management through innovation, partnership and integration. Speakers: Lynn Humber, Atlantic Region Immunization Coordinator, Communicable Disease Control Unit, First Nations & Inuit Health Branch, Health Canada Aminaz Lila, Project Manager, OKAKI Rose Paulley, Nurse Clinician, Manitoba RSV Prophylaxis Program, Winnipeg Children’s Hospital Barbara Nichol, Manitoba Region Immunization Coordinator, First Nations & Inuit Health Branch, Health Canada Session Chair: Erin Henry, Acting Director, Communicable Disease Control, First Nations & Inuit Health Branch, Health Canada

12:30 – 14:30 Canada Hall 2 & 3 (Level 3) NETWORKING LUNCH WITH EXHIBITORS

#cic2014 @cic2014cci

12 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM TUESDAY, DECEMBER 2

13:00 – 14:15 Parliament Foyer (Level 3) DEDICATED POSTER PRESENTATION VIEWING TIME

Delegates are invited to browse the posters and engage with presenters during this dedicated poster viewing session. Vaccinology Student Research Program Posters 1. Persistent rubella seronegativity in an urban Calgary prenatal clinic’s patients – Jong Kim 2. Adverse Events Following Immunization (AEFI) surveillance systems for pregnant women and their infants: A systematic review – Christine Cassidy 3. 2-year-old immunization coverage in Fraser Health, British Columbia: Beyond up-to-date status – Emily Newhouse 4. Pneumococcal serotype replacement in Ontario children <5 years of age, post-introduction of PCV-13 – Chiebere Ogbuneke 5. Duration of pertussis immunity following childhood immunization with DTaP: A systematic review and meta-analysis – Ashleigh McGirr 6. Pertussis vaccine effectiveness in Ontario – Kevin Schwartz 7. Adverse Events Following (AEF) varicella vaccine in Ontario – Emily Shing 8. Influenza risk factors, outcomes, and vaccine effectiveness among immunocompromised adults admitted with acute respiratory illness - 2010/11 to 2013/14: A PCIRN Serious Outcomes Surveillance (SOS) Network Study – Renee Amiro 9. Influenza co-infections among hospitalized adults in Canada: A PCIRN Serious Outcomes Surveillance (SOS) Network Study – Aimee Oliver 10. Early-life immunization with BCG protects the newborn from bacterial sepsis by altering innate immunity – Nelly Amenyogbe 11. Transferring binding protein B - based antigens for protection against Neisseria meningitidis – Jamie Fegan 12. Serological responses to plant-derived H5-VLP influenza vaccines in young and aged mice – Karen Yam 13. Impact of Ontario’s mandatory school pupil immunization legislation – Winnie Siu 14. A scope review on economic evaluations of vaccines in Canada – Ellen Rafferty 15. Impact of pharmacist delivery of influenza vaccines on uptake in Canada – Sarah Buchan 16. Pain mitigation during adult vaccine injections –Kathryn Cull

17. Effect of antigen dose and AS03-adjuvant on the immune response to influenza vaccines in BALB/c mice – Karen Yam 18. Influenza and other respiratory virus co-infections among hospitalized adults in Canada – Aimee Oliver 19. Identifying reportable cases of Adverse Events Following Immunization (AEFI) in the paediatric population – Sophie Bouchard 20. Background incidence rates of Adverse Events Following Immunization (AEFI) of special public health importance in Manitoba – Salah Mahmud 21. Effectiveness of the 2009 Pandemic H1N1 influenza vaccines in preventing H1N1 infection: A meta-analysis – Salah Mahmud

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 13 TUESDAY, DECEMBER 2

22. Impact of influenza vaccination on respiratory illness in school pupils attending private boarding schools in England, 2013/14: A cohort study – Nicholas Brousseau 23. Decreased antibody response against the infecting serotype in vaccine-eligible children with invasive pneumococcal disease in England – Nicholas Brousseau 24. Risk of influenza in healthcare workers compared to other working adults – Brenda Coleman 25. Influenza and other respiratory viruses in children hospitalized during the peak of the 2012/13 influenza season in Québec – Gaston DeSerres 26. Influenza-like illness definition identifies influenza and non-influenza respiratory infections with similar frequency – Gaston DeSerres 27. Burden of influenza among community-dwelling individuals 60 years and older presenting to emergency departments, 2011/12 and 2012/13 – Po-Po Lam 28. Correlation of the BioPlex test and plaque reduction neutralization test for determining antibody immunity to measles virus – Todd Hatchette 29. Respiratory viral infections among hospitalized adults: Not all influenza-like-illness (ILI) is influenza – Todd Hatchette 30. Genotypic and phenotypic characterization of influenza A(H1N1)pdm09 viruses circulating during the 2013/14 season of epidemic resurgence: Findings from the Canadian Sentinel Physician Surveillance Network – Suzana Sabaiduc 31. Clade-level mismatched influenza B/yamagata-lineage viruses circulated during the 2013/14 influenza season: Findings from the Canadian Sentinel Physician Surveillance Network (SPSN) – Suzana Sabaiduc

33. Spontaneous Adverse Drug Reactions Reporting by Physician versus Reporting by Patients in Canada – Rania Dweik 34. Annual reporting on accinev safety in Ontario: Round two – Tara Harris 35. Development of standardized vaccine terminology to support electronic health information – Karen Hay 36. Adverse Events Following Immunization (AEFI) surveillance in Toronto, 2007-2013 –Joanne Cameron 37. Processing of ICSRs of Adverse Events Following Immunization (AEFI) at the Public Health Agency of Canada – Helen Anyoti 38. Safety profile of ICSRs of varicella vaccine submitted to the Public Health Agency of Canada from January, 1 2011 to June 30, 2014 – Helen Anyoti 39. Aggregate reporting of varicella in Ontario 1993-2013: Have we seen a change? – Chi Yon Seo 40. Overview of “popular” signal detection methods in pharmacovigilance with application to Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) using a specific example – Sangook Kim 41. Refining PCR-based surveillance of vaccine-preventable serotypes of streptococcus pneumoniae – Jason LeBlanc 42. Children who receive an “outbreak dose” of MMR vaccine: How timely is the next regularly scheduled dose? – Shannon MacDonald 43. Using administrative data to augment an Adverse Events Following Immunization (AEFI) surveillance system following introduction of a new vaccine – Shannon MacDonald 44. Strengthening of causality assessment of Adverse Events Following Immunization (AEFI): Lessons from 2014 WHO SEAR Inter-country Workshop – Noni MacDonald 45. Trends in Adverse Events Following Immunization (AEFI) in British Columbia, 2005-2011 – Lauren MacDonald 46. Healthcare providers’ perceptions of the vaccine safety surveillance tools and resources in Manitoba – Joselito Montalban 14 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM TUESDAY, DECEMBER 2

47. Active surveillance for community acquired pneumonia among hospitalized Canadian adults, 2011-2013: A PCIRN Serious Outcomes Surveillance (SOS) Network Study – Shelly McNeil 48. Distribution of invasive pneumococcal serotypes in Canada, 2010-2013 – Irene Martin 49. Impact of pneumococcal conjugate vaccines on paediatric invasive pneumococcal disease in Toronto/Peel, 2001- 2014 – Wallis Rudnick 50. Impact of pneumococcal conjugate vaccines on adult invasive pneumococcal disease in Toronto/Peel, 2001-2014 – Wallis Rudnick 51. Epidemiology of invasive pneumococcal disease in Manitoba, 2001 - 2011 – Hasantha Sinnock 52. Invasive pneumococcal disease in immunocompromised patients in southern Ontario, 1995 - 2012 – Altynay Shigayeva 53. The influence of childhood conjugate vaccine introduction on invasive pneumococcal disease in adults with underlying comorbidities – Jason Cabaj 54. Making every shot count: Vaccine administration in Canadian penitentiaries – Jonathan Smith 55. Vaccine-preventable influenza in Canadian federal inmates – Jonathan Smith 56. Seroconversion following hepatitis B vaccination among federal inmates in Canada –Jonathan Smith 57. Pertussis cycles in Canada, 1990-2013 – Jenny Rotondo 58. An update on pertactin-deficient Bordetella pertussis in British Columbia, Canada –Kristy Hayden 59. Recurrent invasive Haemophilus influenzae serotype an infection in an infant – Kristy Hayden 61. Infant respiratory outcomes associated with prenatal exposure to maternal H1N1 influenza vaccination – Robin Ducharme 62. Seasonal variation in rates of emergency room visits and acute admissions following routine infant vaccinations in Ontario – Steven Hawken 63. The impact of influenza vaccination and influenza illness on an individual’s risk of acquiring Guillain-Barré Syndrome: An evidence-based simulation study – Steven Hawken 64. Canadian Adverse Events Following Immunization (AEFI) reports of Guillain Barré Syndrome for vaccines administered from 1987 to 2013 – Barbara Law 65. Guillain-Barré Syndrome after immunization in Canadian children from 1996 to 2012 – Karina Top 66. Determinants of hospitalizations for lower respiratory tract infection in children in Quebec – Zhou Zhou 67. Polio immunity in an urban workplace occupational health program – Judith Shindman 68. The ups and downs of mumps in Ontario: What’s driving the epidemiology? – Catherine Chan 69. Estimating basic and effective reproductive numbers for measles to support global elimination goals –Gillian Lim 70. Achieving verification-standard measles surveillance: A comparative analysis of surveillance attributes and quality indicators across WHO Regions – Fiona Guerra 71. Outbreak of measles, Regina Qu’Appelle Health Region (RQHR), Regina, Saskatchewan, January-February, 2014 – Tania Diener 72. Measles in Canada, 2010-2014: A post-elimination country in a pre-eradication world – Lindsey Sherrard 73. Measles vaccination coverage and age at first dose before the 2011 measles outbreak in Québec, and impact of the Measles Vaccination Campaign – Marie-Noëlle Billard 74. Preliminary surveillance report of the first dose of meningococcal serogroup B vaccine in the Saguenay–Lac- Saint-Jean, Quebec – Marie-Noëlle Billard 75. Clinical and microbiological characteristics of serogroup B invasive meningococcal disease in Quebec – Bruce Tapiero CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 15 TUESDAY, DECEMBER 2

76. Epidemiology and burden of serogroup B invasive meningococcal disease between in Quebec 1997-2010 – Bruce Tapiero 77. Serogroups B, W-135 and Y invasive meningococcal disease in Canada, 2002-2011 – Y. Anita Li 78. A comparison of two enhanced surveillance systems of invasive meningococcal disease in Canada – Y. Anita Li 79. Serogroup B invasive meningococcal disease: Spread of ST-269 clonal complex in space and time from 2003 to 2010 in Quebec – Léna Coïc 80. Vaccine program impact assessment of serogroups C and Y meningococcal disease in Ontario, 2000-2013 – Kenny Wong 81. The epidemiology of invasive meningococcal disease in Manitoba before and after the introduction of the meningococcal conjugate vaccine, Men-C-C, 2001 to 2011 – Salah Mahmud 82. Dramatic reduction in hepatitis B through school-based immunization in Quebec: What could be prevented by adding an infant program? – Vladimir Gilca 83. Recombinant hepatitis B vaccines in preadolescents: Impact of dosage and number of doses on long-term persistence of immunity – Vladimir Gilca 84. Comparison of hemagglutination inhibition and microbead array assays for the measurement of influenza antigen levels in HIV-infected adults – Curtis Cooper 85. Naturally acquired antibody in an Aboriginal population at high risk for invasive haemophilus influenzae Type A disease – Eli Nix 86. Efficacy, immunogenicity of novel 9vHPV vaccine, and effect on abnormal cytology and genital procedures related to HPV31/33/45/52/58 – Emidio DeCarolis 87. Modeling the potential public health and clinical impact of the MF59-adjuvanted seasonal trivalent influenza vaccine in Canada – James A. Mansi 88. Modeling the potential public health and clinical impact of the multicomponent meningococcal B vaccine in Canada – James A. Mansi 89. The amendment and the trend of vaccine injury compensation program in Taiwan - Compensation of BCG vaccine – HsunYin Huang 90. Creating a national immunization schedule: History and policy challenges –Heather MacDougall 91. Low influenza vaccine coverage of children aged 6 to 23 months in Quebec: Why, and what can we do to improve? – Andrée-Anne Paré-Plante 92. Development of an immunization education and policy framework for the pediatricians of Ontario – Paul Roumeliotis 93. Mandating influenza vaccinations for healthcare workers: Windows of opportunity for policy change –Neil Barr 94. Pharmacists’ expanded immunization authority: A global regulatory review – Dana Church 95. Pharmacy students as immunizers: A scoping review of the literature – Dana Church 96. The impact of pharmacists as immunizers on influenza vaccination coverage in Nova Scotia –Jennifer Isenor 97. Pharmacists as immunizers: A survey of New Brunswick pharmacists’ experiences – Jennifer Isenor 98. Estimating shingles vaccine coverage using pharmacy dispensing data – Margaret Russell 99. Accessing influenza immunization: Rural vs. urban parents’ perceptions –Margaret Russell 100. Impact of material and social deprivation on serogroup B invasive meningococcal disease incidence and outcomes in Quebec – Jean-Baptiste Le Meur 101. Uptake of pneumococcal vaccines in the nordic region of Nunavik, Quebec – Jean-Baptiste Le Meur

16 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM TUESDAY, DECEMBER 2

102. «L’Agence de santé déclare la guerre» : veille médiatique de la campagne de vaccination ciblée contre le méningocoque de sérogroupe B au Saguenay–Lac-Saint-Jean, Québec – Eve Dubé 103. Formation des infirmières dans le cadre de la campagne de vaccination ciblée contre le méningocoque de sérogroupe B dans la région du Saguenay–Lac-St-Jean, Québec – Dominique Gagnon 104. Vaccination infantile dans les pays en développement : révision systématique et méta-analyse – Myriam Cielo Pérez Osorio 105. Maintaining the momentum: Key factors influencing acceptance of influenza vaccination among pregnant women following the H1N1 pandemic – Beth Halperin 106. Determining the acceptability of a universal rotavirus vaccination program – Donna MacDougall 107. How Canadians perceive vaccines: A public risk perception survey – Andrea Perna 108. A systematic review of the prevalence of the fear of needles and/or pain as a concern and barrier to vaccination – Anna Taddio 109. Public health nurses’ perceptions and experiences with the FluMist vaccine – Etran Bouchouar 110. Canadian influenza immunization programs: Provincial and territorial strategies for vaccine delivery – Xianfang Liu 111. Influenza vaccination in the Canadian Armed Forces – Martin Tepper 112. Cost-effectiveness of a switch from trivalent to quadrivalent influenza vaccine in Canada –Edward Thommes 113. Randomized Evaluation of Live Attenuated vs. Trivalent Inactivated influenza VaccinEs in Schools (RELATIVES) pilot study: A cluster randomized trial – Jeff Kwong 114. Effect of prior season’s immunization and potential for negative interference on vaccine protection during the 2013/14 influenza season – Catharine Chambers 115. Residual protection from prior 2009 monovalent AS03-adjuvanted pandemic vaccine no longer evident during the 2013/14 influenza season of A(H1N1)pdm09 resurgence –Catharine Chambers 116. Seasonal influenza vaccine coverage in the Canadian population during the 2013/14 season – Julie Laroche 117. Reasons for refusing the seasonal influenza vaccine in the Canadian population during the 2013/14 season – Julie Laroche 118. Immunization-related knowledge, attitudes and behaviours of parents/guardians: Data from the 2011 Childhood National Immunization Coverage Survey (cNICS) – Julie Laroche 119. Performance indicators for monitoring the impact of HPV immunization programs – Julie Laroche 120. HPV vaccination in grade 6 boys in PEI: Evaluating the success of the program’s implementation – Carolyn Sanford 121. The immune response to a reduced dosing schedule of quadrivalent HPV vaccine in girls aged 9 to 13 years: Is it influenced by age, menarchal status or body mass index? – Chantal Sauvageau 122. The effectiveness of publicly funded, school-based HPV among adolescent girls: The Ontario Grade 8 HPV Vaccine Cohort Study – Leah Smith 123. Household contact of young children as a predictor of influenza immunization in young adults in Canada – Trevor Arnason 124. Making immunization decisions for school-aged children: A rapid review – Paulette Whyte 125. Immunization exemptions for school-aged children in Toronto in 2006/07 to 2012/13 school years – Vinita Dubey

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 17 TUESDAY, DECEMBER 2

127. Introducing new vaccines in peripheral health centres: Opportunities, expectations and concerns: The case of MenAfriVacTM in Burkina Faso – Aboubakary Sanou 128. An mHealth-based initiative to increase vaccine acceptance and uptake of immunization services in India: Concept and feasibility – Nanor Minoyan 129. Non-publicly funded vaccines: Clinical practice project – William Abelson 130. Characteristics of medical information requests on influenza vaccines received at Novartis Pharmaceuticals Canada Inc. during the 2013/14 influenza season – Jacques Lemay 131. Influenza vaccination refusal among racialized groups: A qualitative study –Nancy Akor 132. Community pharmacists’ knowledge, beliefs, and attitudes towards immunization in Québec –Pascal Bedard 133. Build it and they will come? Early lesson larned from a US consumer empowerment immunization records pilot – Michael Popovich 134. Attributes and operations of an effective Vaccine Inventory Management System (VIMS) –Shawn Box 135. AVALON: Advanced Vaccinology Learning Online – Monica Durigon 136. Empowering health professionals to address vaccine hesitancy – Jill Fediurek 137. Improving our data: A quality improvement initiative to enhance vaccine preventable disease surveillance in Ontario – Jill Fediurek 138. Long-term effect of a birth vaccination promotion strategyThomas – Lemaître 139. Improving client-oriented service through interviews of parents receiving recall reminders – Michelle Murti 140. Vaccine hesitation among Quebec parents of children aged 2 months to 5 years – Maryse Guay 141. What is the best way to organize vaccination services for Quebec children aged 0 to 5 years? – Maryse Guay 142. Giving MMR vaccine to children who receive regular blood transfusions – Tania Weisgerber 143. The Immunization Communication Tool (ICT): A tool for enhancing immunization communication –Shaila Jiwa 144. Online influenza immunization course for health professionals in British Columbia –Shaila Jiwa 145. Do it right keep for life: Immunization record documentation – Margaret McIntyre

#cic2014 @cic2014cci

18 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM TUESDAY, DECEMBER 2

CONCURRENT SESSIONS 14:30 – 16:00

Monitoring & Surveillance Room 206 Innovative approaches to vaccine-preventable disease surveillance As data continue to permeate societies around the globe, the digital information age in which we now live continues to grow and evolve. Old disciplines are merging as new ones are emerging and citizens have more information available to them, almost instantaneously, than has ever been the case before. This session will explore the role of vaccine- preventable disease surveillance within this changing landscape. Presenters will discuss traditional and novel surveillance approaches, their implications on analyses related to vaccine-preventable disease epidemiology, citizen engagement and some of the challenges that will need to be overcome to move public health forward in this information-rich age. Learning Objectives: • Identify and critically appraise novel approaches in vaccine-preventable disease surveillance. • Describe novel methods for the collection, analysis and interpretation of unstructured data. • Explore existing and future challenges for public health in the digital age. Speakers: David Buckeridge, Associate Professor, Clinical and Health Informatics Research, McGill University Daniela Paolotti, Research Leader, ISI Foundation Ann Jolly, Associate Professor, Department of Epidemiology and Community Medicine, University of Ottawa Session Chair: Philip Abdelmalik, Senior Epidemiologist/Advisor, Situational Awareness and Operations, Centre for Emergency Preparedness and Response, Health Security Infrastructure Branch, Public Health Agency of Canada

Vaccine Research & Development Oral Abstract Session 1 Room 202 Bronchiolitis in Indigenous infants: A review of the incidence and risk factors in Canada, the United States, Australia and New Zealand – Joanne Langley Invasive meningococcal disease in Canada: Identifying research priorities by virtual Research Round Table (RRT) – Simon Dobson Evaluation of meningococcal C conjugate vaccine programs in Canadian children – Julie Bettinger Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) – Susanne Huijts Safety and tolerability of a novel 9-valent PV vaccine in boys/girls aged 9 to 15 and women aged 16 to 26 – Emidio DeCarolis Oral Abstract Session 2 Room 204 Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies – Shelly McNeil Immune trafficking of plant-derived influenza H5-based virus-like particles –Katie Young Challenging HPV vaccines manufacturers’ recommendations: Are we giving too many doses of HPV vaccine to preadolescents? – Vladimir Gilca Collaborations in support of HIV vaccine research and development in Canada – Renee Barclay Ebola virus vaccine VSVrG-EBOVGP: From design to delivery – Judie Alimonti

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 19 TUESDAY, DECEMBER 2 • 14:30 - 16:00

Policy-making Room 208 Vaccine schedules: The opportunities of off-label and innovative uses of vaccines Based on available scientific evidence, various vaccine programs have been implemented, using vaccines in innovative ways. These off-label uses have been evaluated and the results will be presented. This session will present the results to date of the evaluation of the 2-dose Human Papillomavirus Vaccine (HPV) schedule, the use of live-attenuated influenza virus (LAIV) in children with chronic conditions, and alternative pneumococcal vaccine schedules. Learning Objectives: • Describe how and why innovative vaccination schedules are implemented. • Recognize the importance of evaluating innovative and off-label vaccination schedules. • Identify factors facilitating the development and implementation of innovative vaccination schedules. Speakers: Philippe DeWals, Professor, Department of Social and Preventive Medicine, Laval University & Public Health Specialist, Institut national de santé publique du Québec Caroline Quach, Pediatric Infectious Disease Consultant and Medical Microbiologist, Infection Control and Prevention, The Montreal Children’s Hospital, McGill University Chantal Savageau, Médicin-conseil, Institut national de santé publique du Québec Session Chair: Caroline Quach, Pediatric Infectious Disease Consultant and Medical Microbiologist, Infection Control and Prevention, The Montreal Children’s Hospital, McGill University

Programs Room 210 Condition-of-service influenza prevention in health care settings Patient safety is a primary concern of influenza control policies. Research evidence clearly demonstrates that immunizing health care workers against influenza reduces the risk of influenza transmission to patients and residents of long-term care facilities. However, influenza immunization of health care workers as a condition of service has raised several policy, programmatic, and professional ethics issues. This session will draw upon recent Canadian experiences with condition-of- service policies to explore these issues. Learning Objectives: • Discuss the research evidence that informs the control of influenza in health care settings policy. • Discuss experiences with the development, implementation and evaluation of condition-of-service influenza prevention policies. • Understand the ethical and legal considerations associated with influenza prevention in health care settings. Speakers: Armand H. Antommaria, Director, Ethics Center, Attending Physician, Division of Hospital Medicine, Cincinnati Children’s Hospital Medical Center & Associate Professor, UC Department of Pediatrics Marilyn Babineau, Regional Manager, Employee Health and Wellness, Horizon Health Network Allison McGeer, Director, Infection Control, Mount Sinai Hospital & Professor, Epidemiology, Dalla Lana School of Public Health, University of Toronto Session Chair: Bonnie Henry, Deputy Provincial Health Officer, British Columbia

20 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 14:30 - 16:00 • TUESDAY, DECEMBER 2

Practice Room 215 Vaccine hesitancy to vaccine acceptance: What actually works? This session will focus on key elements underpinning vaccine acceptance and evidence-based interventions to reduce vaccine refusal and vaccine hesitancy. Pain will be explored as a factor of vaccine hesitancy. Specifically, we will describe the prevalence of needle pain and needle fear as determinants of vaccination non-compliance and review evidence- based methods to mitigate pain and fear. Finally, tools and implementation strategies for successful uptake will be highlighted for patients and immunizers. Learning Objectives: • Summarize the key elements underpinning vaccine acceptance. • Review evidence-based approaches for addressing barriers to vaccine acceptance, with a focus on injection-induced pain and fear. • Identify relevant tools and implementation approaches. Speakers: Ève Dubé, Researcher, Institut national de santé publique du Québec, Laval University Anna Taddio, Professor, Leslie Dan Faculty of Pharmacy, University of Toronto & Adjunct Scientist and Clinical Pharmacist, SickKids Hospital Session Chair: Noni MacDonald, Professor, Department of Pediatrics, IWK Children’s Hospital, Dalhousie University

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 21 TUESDAY, DECEMBER 2

16:00 – 17:30 Canada Hall 2 & 3 WELCOME RECEPTION End the first day of sessions with a casual networking reception with exhibitors. Meet fellow attendees from across the country and sample food and beverage selections as you mingle, network and make lasting connections. During the reception, world-renowned photographer Anne Geddes will highlight the Protecting Our Tomorrows global campaign.

Protecting Our Tomorrows: Portraits of Meningococcal Disease Protecting Our Tomorrows is a global campaign with world-renowned photographer and child-health advocate, Anne Geddes. The campaign is aimed at educating parents about the threat of meningococcal disease and the importance of early detection and prevention through inspirational photographs that celebrate survivors and honor those who lost their lives to the disease. The Protecting Our Tomorrows: Portraits of Meningococcal Disease image collection features 15 survivors and their families from many different countries and cultures – including Canada – and is available for free to the public in an eBook. This project has been made possible through a collaboration with Anne Geddes, Novartis Vaccines and the Confederation of Meningitis Organisations (CoMO).

22 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM Novartis Vaccines: For us, caring begins with prevention.

Our family of vaccines includes:

AGRIFLU, BEXSERO, FLUAD, IXIARO, MENJUGATE, MENVEO and RabAvert are registered trademarks. Product Monographs available on request. Printed in Canada 14VCN006E © Novartis Pharmaceuticals Canada Inc. 2014

Agence: CDM MONTREAL CYAN MAGENTA YELLOW BLACK CDM MONTREAL Client: NOVARTIS P02703 Sujet: VACCINS PREVENTION Format: 8.5 X 11 Couleur: 4C Publications: CANADIAN IMMUNIZATION CONFERENCE ANGLAIS TUESDAY, DECEMBER 2

17:00 Parliament Foyer Vaccinology Student Research Program

Led by the Canadian Association for Immunization Research and Evaluation (CAIRE) with co-funding from the Canadian Institutes of Health Research (CIHR), twenty-two students submitted applications to the Vaccinology Student Research Program (VSRP). Projects were evaluated based on pertinence to immunization programs in Canada, the methods used as well as originality, timeliness and effort involved. Five students were awarded a travel bursary to attend CIC 2014. During this dedicated poster viewing time, students will have the opportunity to discuss their research with experienced Canadian vaccinology researchers. One student will be selected as the recipient of an educational bursary from the Dr. Bernard Duval Foundation. The winning student will be announced on Thursday, December 4, prior to the Dr. John Waters lecture. We encourage you to take the opportunity to browse the posters and engage with presenters. Session Chair: Dr. Margaret Russell, Associate Professor, Cumming School of Medicine, the University of Calgary & Chair, Vaccinology Student Research Program Travel Bursary Winners: 3. 2-year-old immunization coverage in Fraser Health, British Columbia: Beyond up-to-date status – Emily Newhouse, Postdoctoral Fellow, University of British Columbia 5. Duration of pertussis immunity following childhood immunization with DTaP: A systematic review and meta-analysis – Ashleigh McGirr, PhD Student, University of Toronto 10. Early-life immunization with BCG protects the newborn from bacterial sepsis by altering innate immunity – Nelly Amenyogbe, PhD Student, University of British Columbia 12. Serological responses to plant-derived H5-VLP influenza vaccines in young and aged mice – Karen Yam, Postdoctoral Fellow, Research Institute of the McGill University Health Centre 16. Pain mitigation during adult vaccine injections – Kathryn Cull, Medical Student, Faculty of Medicine, Dalhousie University Student Participants 1. Persistent rubella seronegativity in an urban Calgary prenatal clinic’s patients – Jong Kim, Resident, University of Calgary 2. Adverse Event Following Immunization (AEFI) surveillance systems for pregnant women and their infants: A systematic review – Christine Cassidy, PhD Student, Dalhousie University 4. Pneumococcal serotype replacement in Ontario children <5 years of age, post-introduction of PCV-13 – Chiebere Ogbuneke, Resident, Northern Ontario School of Medicine 6. Pertussis vaccine effectiveness in Ontario – Kevin Schwartz, Masters Student, University of Toronto 7. Adverse Events Following (AEF) varicella vaccine in Ontario – Emily Shing, Masters Student, University of Toronto 8. Influenza risk factors, outcomes, and vaccine effectiveness among immunocompromised adults admitted with acute respiratory illness - 2010/11 to 2013/14: A PCIRN Serious Outcomes Surveillance (SOS) Network Study – Renee Amiro, Medical Student, Faculty of Medicine, Dalhousie University 9. Influenza co-infections among hospitalized adults in Canada: A PCIRN Serious Outcomes Surveillance (SOS) Network Study – Aimee Oliver, Nursing Student, Dalhousie University 11. Transferring binding protein B - based antigens for protection against Neisseria meningitidis – Jamie Fegan, PhD Student, University of Calgary 13. Impact of Ontario’s mandatory school pupil immunization legislation – Winnie Siu, Postdoctoral Fellow, University of Toronto 14. A scope review on economic evaluations of vaccines in Canada – Ellen Rafferty, PhD Student, University of Saskatchewan 15. Impact of pharmacist delivery of influenza vaccines on uptake in Canada – Sarah Buchan PhD Student, University of Toronto

24 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM What We Do As a global biopharmaceutical company, our activities touch many people’s lives. We work closely with all our stakeholders to understand their challenges and how we can combine our skills and resources to achieve a common goal: improved health. Because Health Connects Us All

astrazeneca.ca

The AstraZeneca logo is a registered trademark of AstraZeneca AB.

AZ_CorpAd_CIC_2014-halfpage.indd 1 14/10/2014 3:54:46 PM

MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB. BUT THEY BEGIN IN THE HEART.

For more than 150 years, a very special passion has driven the people at Merck. Our goal is to develop medicines, vaccines, consumer care and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we’re doing it, with a long-standing commitment to research and development. We’re just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we’ll meet that challenge. With all our heart.

CO-DEVELOPED ACCREDITED LEARNING ACTIVITIES 7:00 – 8:30

Are we on the right track toward HPV-related cancer and disease elimination? Learning from Canada’s experience Room 201 This symposium will focus on the impact of HPV immunization on HPV-related diseases and cancers in different Canadian jurisdictions and worldwide. As different vaccination programs have been implemented, the advantages of the various vaccination and screening programs will be reviewed and successes and/or disadvantages highlighted. This symposium will also describe innovative ways to vaccinate populations that may be more difficult to reach. Finally, in light of the upcoming 9-valent HPV vaccine, there is a need to reflect on its potential impact on future vaccination programs and review cost-effectiveness data of different HPV vaccination programs. Learning Objectives: • Discuss what has been learned since the launch of HPV vaccines including their impact on HPV associated health and psychosocial burden in Canada. • Discuss innovative ways to increase vaccine uptake in the target populations. • Recognize present and potential future impact of HPV vaccination on HPV associated diseases. Speakers: Vivien Brown, Assistant Professor, Department of Family and Community Medicine, University of Toronto Chantal Sauvageau, Médecin-conseil, Institut national de santé publique du Québec, Centre de recherche du CHU de Québec Marc Steben, Medical advisor, STI unit, Institut national de santé publique du Québec Session Chair: Carolyn Pim, Associate Medical Officer of Health, Associate Medical Office of Health, Ottawa Public Health This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Association of Medical Microbiology and Infectious Disease (AMMI) Canada. The program was co-developed with AMMI Canada and Merck Canada Inc. and was planned to achieve scientific integrity, objectivity and balance.

Influenza Vaccination: Addressing an unmet need in older adults Room 215 Influenza remains the single most important cause of excess disability and mortality during the winter months. In spite of widespread influenza vaccination programs leading to demonstrated cost-savings in the over 65 population, hospitalization and death rates for acute respiratory illnesses continue to rise. Inflammaging, the chronic elevation of inflammatory cytokine levels have been linked to increasing frailty and increased susceptibility to the serious complications of influenza. These complications particularly seen in hospitalized older adults lead to an accumulation of multiple health and functional deficits and progression of frailty. Thus, an important goal of vaccination programs is to prevent hospitalizations or delays in discharge due to complications of influenza illness. New influenza vaccines are needed to address this unmet need in older adults. Learning Objectives: • Describe “inflammaging” and how it impacts the immune response to influenza and influenza vaccination. • Explore the effects of increasing frailty on the immune system of older adults in relation to influenza. • Review influenza vaccine effectiveness for prevention of serious illness and appreciate the burden of disease in older adults admitted to acute care. • Review results of recent randomized trials of new high-dose influenza vaccine and how improvements in vaccine efficacy may impact the health of older Canadians.

26 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM WEDNESDAY, DECEMBER 3

Speakers: Melissa Andrew, Assistant Professor, Division of Geriatric Medicine, Dalhousie University Allison McGeer, Director, Infection Control, Mount Sinai Hospital & Professor, Epidemiology, Dalla Lana School of Public Health, University of Toronto Shelly McNeil, Professor, Department of Medicine and Division of Infectious Diseases, Faculty of Medicine, Dalhousie University Session Chair: Shelly McNeil, Professor, Department of Medicine and Division of Infectious Diseases, Faculty of Medicine, Dalhousie University This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Paediatric Society (CPS). The program was co-developed with CPS and Sanofi Pasteur and was planned to achieve scientific integrity, objectivity and balance.

Insights and lessons learned from the introduction and utilization of quadrivalent flu vaccine in the US, UK and Canada Room 213 The session is designed to provide the audience an overview of the experiences and lessons learned from other public health agencies in the US and UK. The session will explore the impact of different models for vaccine delivery as well as key lessons learned from the transition process from a trivalent version to a quadrivalent version of the flu vaccine. This information will be supplemented with the most recent scientific data that led to the ACIP recommendation for a preferential use in children under 8 in the US. In addition, the session will explore the Canadian experience with the introduction, acceptance and utilization of a new intranasal flu vaccine option for children. Learningsession Objectives: cancelled • Describe the rationale, insights and experience from the UK paediatric and school age flu vaccination programs. • List the lessons learned in the US public health system from transitioning from trivalent flu vaccine to quadrivalent flu vaccine. • Demonstrate understanding and knowledge of intranasal vaccines and their role in the paediatric flu vaccine program. • Summarize the lessons learned from the introduction of a new intranasal vaccine into the Canadian market and public health program. Speakers: Speakers to be confirmed Session Chair: Anna Taddio, Professor, Leslie Dan Faculty of Pharmacy, University of Toronto & Adjunct Scientist and Clinical Pharmacist, SickKids Hospital This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Paediatric Society (CPS). The program was co-developed with CPS and AstraZeneca and was planned to achieve scientific integrity, objectivity and balance.

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 27 1 Man’s vision 100 years oF innovaTion

over 1,000 sTrong

Dr. John g. FiTzgeralD, our FounDer anD a pioneer oF public healTh in canaDa, envisioneD a worlD in which no one suFFers or Dies FroM a vaccine-prevenTable Disease. a century later, our over 1,000 employees continue to research, develop and manufacture groundbreaking vaccines to help further this cause. inspired by Fitzgerald’s vision, and a legacy of innovative products and technologies, our commitment to providing vaccines that help improve that improve the quality of life for millions around the globe has never been stronger. facebook.com/SanoﬁPasteurCanada100 WEDNESDAY, DECEMBER 3

9:00 – 10:30 Canada Hall 1 (Level 3) WELCOME & PLENARY II

Celebrating the National Advisory Committee on Immunization 50th Anniversary The National Advisory Committee on Immunization (NACI) marked its 50th anniversary in October 2014. NACI has provided immunization guidance for vaccine use in Canada since 1964, including the development of the Canadian Immunization Guide beginning in 1979, which continues to be a valued resource for health professionals and provincial and territorial immunization programs. The field of vaccinology has evolved over the years from a few vaccines in 1964 to currently over 60 authorized vaccines for 24 different diseases included in the current Canadian Immunization Guide. The success of NACI over the last 50 years is a result of the commitment, dedication, and expertise of its volunteer members. NACI membership and its activities have evolved over the years, and with an increasingly complex landscape, NACI will need to continue to evolve to meet the needs for immunization information in Canada. The presentation will highlight NACI’s history and its accomplishments over the past 50 years. • Presented by: Bryna Warshawsky, Public Health Physician, Public Health Ontario (NACI Chair June 2011- June 2014)

Plenary II: Lessons from the Panic Virus – Communicating with parents and the public Six years ago, Seth Mnookin was surprised to learn that some of his well-educated peers – lawyers, professors, computer programmers – were delaying or even skipping vaccines. That prompted his investigation into how we, as individuals and as a society, decide what counts as the “truth.” The result of his research was his 2011 book The Panic Virus, which explores the history and tactics of the anti-vaccine movement. Since then, Mnookin has continued to focus on public communication on vaccines. In his plenary presentation, he will discuss the roots of parental anxiety surrounding vaccines, the difficulty in combating unfounded rumours, and the dearth of research on the proper way to deal with vaccine hesitancy. He will also propose a handful of measures that could serve to lessen parental anxiety – and provide evidence that the anti-vaccine message that took hold in the late 1990s is losing ground.

Learning Objectives: • Explain why, even though science has so clearly shown that the evidence argues against a relationship between vaccines and autism, some people still believe there is a link. • Explore how some mass media failed to adequately explain the fundamental but essential difference between correlation and causation. • Demonstrate evidence that the anti-vaccine movement is changing. Speakers: Seth Mnookin, Author, The Panic Virus & Associate Director, MIT Graduate Program in Science Writing Session Chair: Ian Culbert, Co-chair, CIC Organizing Committee & Executive Director, Canadian Public Health Association

10:30 – 11:00 Canada Hall 2 & 3 (Level 3) REFRESHMENT BREAK

10:30 – 17:30 Canada Hall 2 & 3 (Level 3) EXHIBIT PROGRAM

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 29 WEDNESDAY, DECEMBER 3

CONCURRENT SESSIONS 11:00 – 12:30

Monitoring & Surveillance Room 206 #Success! – Immunization registries @work Immunization registries are invaluable tools for health care providers and health system planners, so why is it so challenging to implement or upgrade one? In this inspiring presentation, three successful immunization registry projects demonstrate that functional systems are responsive and useable. This presentation highlights examples where a Public Health need drove the registry to expand its scope, transforming from a repository of information to a registry that is a valuable staple of daily practice. To round out the presentation, Manitoba eHealth will describe their proven project management structure that places health “business” needs at the centre of the project’s success. When so much of the registry development process sits with legislative officials who hold the funds, and technical experts who build the systems, participants will be empowered to evaluate their current registry situation in order to create new solutions. Learning Objectives: • Identify successful registries. • Assess their organization’s registry and seek out enhancements that meet their population’s needs. • Recognize components of successful registries: system usability, reminder-recall functionality, capture of physician- provided immunization, interoperable terminology. • Recognize how strategic partnerships can increase project success. Speakers: Arielle Goldman Smith, Program Consultant, MIMS Program Project Coordinator, Manitoba Health Debbie Honke, Director, Project Management Office, Manitoba eHealth Karl Mallory, Project Manager, BC First Nations Panorama Implementation Project Session Chair: Julie Laroche, Manager, Immunization Assessment and Information, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada

Vaccine Research & Development Room 208 Challenges with current vaccines With new vaccines come benefits and new (sometimes unexpected) challenges. This session will focus on challenges presented by current vaccines and will offer some potential solutions. Some of the questions to be discussed include: Does immunity wane rapidly after immunization with a cellular pertussis vaccine? Is there any benefit to use the conjugated pneumococcal vaccine in mature adults? Is the risk of intussusception after rotavirus vaccine worrisome and how does it compare to the actual benefit of the vaccine? Learning Objectives: • Discuss the impact of a change in pertussis vaccine formulation on pertussis transmission and disease frequency. • Explain the opportunities and challenges of conjugate pneumococcal vaccine use in older adults. • Compare and contrast the risks and benefits of an infant rotavirus vaccine program.

30 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 11:00 - 12:30 • WEDNESDAY, DECEMBER 3

Speakers: Shelley Deeks, Medical Director, Immunization and Vaccine Preventable Diseases, Public Health Ontario & Associate Professor, Dalla Lana School of Public Health, University of Toronto Scott Halperin, Medical Director, Clinical Research and Vaccine Challenge Unit, Canadian Centre for Vaccinology, & Professor, Department of Pediatrics, Dalhousie University Allison McGeer, Director, Infection Control, Mount Sinai Hospital & Professor, Epidemiology, Dalla Lana School of Public Health, University of Toronto Session Chair: Anne Pham-Huy, Pediatric Physician, Infectious Diseases, CHEO

Policy-making Oral Abstract Session 1 Room 202 Economic evaluation of vaccines in Canada: A systematic review – Ayman Chit Cost-effectiveness of quadrivalent vs monovalent vaccination against meningococcal disease in Canada –Thomas Delea Cost-effectiveness analysis of different HPV vaccination strategies using the Cancer Risk Management Model (CRMM) and HPV Microsimulation Model (HPVMM) – Saima Memon An analytical framework for the post-implementation evaluation of immunization programs in Canada – Maria Eugenia Espinoza Modeling the transmission dynamics and economics of pertussis booster vaccine for Canadian adolescents and adults – Hossein ZivariPiran Oral Abstract Session 2 Room 204 Mandatory influenza vaccination of healthcare workers: What past legal cases reveal about future policy-making – Vanessa Gruben Drawing attention to recommended but unfunded vaccines in Canada – David Scheifele British Columbia Influenza Prevention Policy: The 6Ps from the first year of implementation –Donna MacDougall Household chaos plays a significant role in children’s immunization status at age two – Christopher Bell Patient perspectives on pharmacists as immunizers: A scoping review – Dana Church

Programs Room 210 Lessons learned and strategies for maintaining measles elimination 2013 was a year marked by outbreaks of measles in numerous jurisdictions across the country. This session will provide an overview of the epidemiology of measles, importation risks to Canada, outbreaks, and immunization coverage, as well as intervention strategies aimed at reducing the risk of disease transmission. Learning Objectives: • Discuss the national and international status of measles elimination, and issues that impact Canada’s ability to maintain elimination. • Identify public health interventions in response to recent outbreaks in Canada. • Describe strategies to reduce the risk of importations and further transmission of measles in the post-elimination era in the Americas.

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 31 WEDNESDAY, DECEMBER 3 • 11:00 - 12:30

Speakers: Natasha Crowcroft, Chief, Infectious Diseases, Public Health Ontario & Associate Professor, Laboratory Medicine and Pathobiology, Dalla Lana School of Public Health, University of Toronto Po Po Lam, Research Fellow, Mount Sinai Hospital Martin Lavoie, Deputy Chief Medical Officer of Health, Alberta Health Lisa Mu, Medical Health Officer, Fraser Health Authority Session Chairs: Diego Garcia, A/ Director, Communicable Disease Control, First Nations and Inuit Health Branch, Health Canada

Practice Room 215 Are we forgetting adults? Update on immunization of the 18-year-old and older While we have excellent national guidelines in Canada with regard to adult immunization, implementation issues still abound. Primary care workers are overwhelmed with demands, and given the complexity of issues around vaccines; the latter are often overlooked due to workers’ time constraints, lack of organization and other pressing ambulatory issues. This session will look at the routine immunizations for adults with an emphasis on seniors and travel vaccines as these relate to new outbreaks of vaccine-preventable diseases in certain parts of the world. There will be a focus on how to provide clear messages to patients, addressing some of the management concerns faced by Canadian primary care providers, and the power and importance of physician recommendation and support will also be discussed. Learning Objectives: • Describe the need to improve the vaccination coverage rate in the Canadian adult population. • Review the recommendations for routine adult immunization and select travel immunizations, influenza vaccination for seniors and challenges with the younger adult population. • Discuss the common patient management issues, including the dilemma of recommended but unfunded vaccine, barriers in primary care, vaccine hesitancy and media misinformation. Speakers: Vivien Brown, Family Physician & Vice-President, Medical Affairs, Medisys Health Heather Dixon, Director, CFFM International Travel and Immunization Clinic, The Centre for Family Medicine Shelly McNeil, Associate Professor, Department of Medicine and Division of Infectious Diseases, Faculty of Medicine, Dalhousie University Session Chair: Shelley McNeil, Professor, Department of Medicine and Division of Infectious Diseases, Faculty of Medicine, Dalhousie University

12:30 – 14:30 Canada Hall 2 & 3 (Level 3) NETWORKING LUNCH WITH EXHIBITORS

32 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM WEDNESDAY, DECEMBER 3

CO-DEVELOPED ACCREDITED LEARNING ACTIVITIES 12:45 ‐ 14:15

Two B’s? Or not Two B’s? Examining quadrivalent influenza vaccines Room 201 Influenza poses a substantial public health burden with considerable morbidity and mortality. The annual trivalent influenza vaccine (TIV) offers protection against two influenza A strains and one influenza B strain. Quadrivalent influenza vaccines offer added coverage for a second influenza B strain. To evaluate whether or not quadrivalent vaccines should be introduced issues such as the epidemiology and disease burden of influenza B, the effectiveness of the vacccines, and the cost-benefit need to be examined. Learning Objectives: • Describe the epidemiology of influenza in Canada. • Recognize the burden of influenza B in Canada. • Compare the characteristics (including effectiveness, immunogenicity, and safety) of quadrivalent influenza vaccines to trivalent influenza vaccines. • Identify knowledge gaps with regards to the efficacy and effectiveness of quadrivalent influenza vaccines. • Discuss the potential impact of receiving a quadrivalent influenza vaccine on influenza-associated outcomes. • Consider the potential cost-benefit of quadrivalent influenza vaccines. Speakers: Joanne Langley, Professor of Pediatrics, Faculty of Medicine, Dalhousie University Dat Tran, Staff Physician, Infectious Diseases, The Hospital for Sick Children & Assistant Professor, Paediatrics, University of Toronto Bryna Warshawsky, Public Health Physician, Public Health Ontario

Session Chair: Noni MacDonald, Professor, Department of Pediatrics, IWK Children’s Hospital, Dalhousie University This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Association of Medical Microbiology and Infectious Disease (AMMI) Canada. The program was co-developed with AMMI Canada and the Canadian Public Health Association and was planned to achieve scientific integrity, objectivity and balance.

What Canadian health care professionals want to know about meningococcal B vaccination – An evidence‐based approach Room 213 Invasive meningococcal disease (IMD) remains a concern for health care providers, public health, and parents alike. Since the decline in serogroup C (MenC) cases following the initiation of MenC immunization programs, serogroup B (MenB) has become the most common IMD serogroup in Canada. Recent vaccine research offers new options and solutions against MenB which tends to strike in infants and young adolescents. This symposium will take an in‐depth look at the potential clinical and societal impact of introducing MenB immunization into routine clinical practice in Canada. Expanding on a recently conducted expert forum addressing frequently asked questions from health care providers pertaining to MenB disease and the MenB vaccine, the challenges and opportunities around the introduction of a meningococcal B vaccine into the routine clinical practice will be discussed. This symposium will address the immediate need for answers to commonly asked questions around the introduction of a MenB vaccine.

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 33 WEDNESDAY, DECEMBER 3

Learning Objectives: • Describe meningococcal B disease in Canada. • Discuss the safety and immunogenicity of the multicomponent meningococcal B vaccine. • Respond to commonly asked questions regarding the introduction of the meningococcal B vaccine into the routine Canadian immunization schedule. Speakers: Ronald Gold, Honorary staff, the Hospital for Sick Children Tajdin Jadavji, Professor, Department of Microbiology, Immunology & Infectious Diseases, University of Calgary Marc Lebel, Pediatric Infectious Diseases, CHU Sainte-Justine Allan Ronald, Distinguished Professor Emeritus, Department of Medical Microbiology, University of Manitoba Marla Shapiro, Associate Professor, Department of Family and Community Medicine, University of Toronto John Yaremko, Assistant Professor, Paediatrics, McGill University Session Chair: Marla Shapiro, Associate Professor, Department of Family and Community Medicine, University of Toronto This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Paediatric Society (CPS). The program was co-developed with CPS, the International Centre for Infectious Diseases and Novartis and was planned to achieve scientific integrity, objectivity and balance.

Medicago’s plant based technology has the potential to offer more potent vaccines with speed and cost advantages over competitive technologies. Its pipeline includes a pandemic and quadrivalent seasonal flu vaccines in advanced clinical development, a rotavirus vaccine and antibodies. The Company also intends to expand development into other areas such as biosimilars. Medicago is headquartered in Quebec City, Canada where it operates R&D labs and a pilot-scale cGMP facility. In the USA the Company operates a cGMP commercial-scale facility in the Research Triangle Park, NC, and works with collaborators at Genopole in Evry, France and at Cape Town University in South Africa. In September 2013. Mitsubishi Tanabe Pharma Corporation became the major shareholder of Medicago. www.medicago.com.

34 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM WEDNESDAY, DECEMBER 3

CONCURRENT SESSIONS 14:30 – 16:00

Monitoring & Surveillance Room 206 Can it? Will it? Did it? Causal association between vaccines and adverse events In an immunization context, causality can be defined as the relation between an event (immunization) and a second event (adverse outcome) where the second event is understood to be the consequence of the first. Many events are blamed on vaccines and/or immunization and in some cases there is definitive proof that the vaccine caused the event. Causality is a difficult concept to understand, to communicate and to establish or refute. Context – present, past and future as well as individual versus population – is also critically important. This session will explore causality in three different contexts, providing real-life examples to help practitioners incorporate causality concepts into their daily practice. Learning Objectives: • Describe the difference between temporal association and causation. • Identify approaches to establish whether or not a vaccine can or did cause an adverse event in populations or individuals. • Explain vaccine-related risk effectively. Speakers: Simon Dobson, Clinical Investigator, Child and Family Research Institute & Clinical Associate Professor, Department of Pediatrics, University of British Columbia Linda Lévesque, Associate Professor, Department of Public Health Sciences, Queen’s University Noni MacDonald, Professor, Department of Pediatrics, IWK Children’s Hospital, Dalhousie University Session Chair: Barbara Law, Chief Vaccine Safety, Surveillance and Outbreak Response Division, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada

#cic2014 @cic2014cci

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 35 WEDNESDAY, DECEMBER 3 • 14:30 - 16:00

Vaccine Research & Development Room 210 Innovations in influenza vaccinology This forward-looking session will focus on newer influenza vaccines and new insights into protective immunity. The potential of plant-derived and other novel antigens and adjuvants will be described, including prospects for vaccines that prolong and broaden protection (i.e., “universal” vaccines). Advances in understanding protective immunity will be outlined, including correlates of protection and options for more effective priming of desirable responses. Learning Objectives: • Describe recent advances in influenza vaccine development and their rationale. • Explain how immune responses differ depending upon the nature of vaccine stimulus and their potential implications for clinical protection. Speakers: Rachelle Salomon, Program Officer, Respiratory Diseases Branch, National Institute of Allergy and Infectious Diseases Kanta Subbarao, Chief, Emerging Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases Brian Ward, Associate Professor, Centre for the Study of Host Resistance, McGill University Session Chairs: Marc Ouellette,Scientific Director, Institute of Infection and Immunity, Canadian Institutes of Health Research David Scheifele, Senior Clinician Scientist, Director, Vaccine Evaluation Centre, Child and Family Research Institute & Professor, Division of Infectious and Immunological Diseases, University of British Columbia

Policy-making Room 208 Making recommendations on vaccines: Marrying science and best judgement The processes by which new vaccines receive recommendations for use need to be evidence-based and transparent. Various processes exist to develop recommendations for vaccine use in Canada. Using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, this session will highlight how advisory committees abroad and in Canada appraise available evidence to make recommendations on vaccines and how this evidence is used and developed at the provincial/territorial level. Learning Objectives: • Describe processes for considering evidence for vaccine use and programmes, such as evidence-based decision-making and GRADE. • Identify what information is most critical, what might delay an approval and how missing information is dealt with. • Explain how recommendations on vaccine use are made in Canada. • Compare how provinces and territories apply national recommendations. Speakers: Jon Abramson, Chair and Professor, Department of Pediatrics, Wake Forest University Baptist Medical Center Gaston DeSerres, Medical Epidemiologist, Institut national de santé publique du Québec & Professor, Faculty of Medicine, Laval University Bryna Warshawsky, Public Health Physician, Public Health Ontario Session Chair: Ian Gemmill, Medical Officer of Health, Kingston, Frontenac and Lennox & Addington Public Health & Associate Professor, Department of Health and Epidemiology, Family Medicine, Queen’s University

36 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 14:30 - 16:00 • WEDNESDAY, DECEMBER 3

Programs Oral Abstract Session 1 Room 202 I Boost Immunity campaign – Ian Roe Public health partnerships: The final report on a best practice model for vaccine safety in British Columbia – Lauren MacDonald Vaccination attitudes and mobile readiness: A survey of expectant and new mothers –Katherine Atkinson Meningococcal education program for Quebec physicians: How results have changed 2 years after the initial program – Marc Lebel Mass vaccination against group B meningococcal disease in Saguenay, Quebec: Acceptability by parents and health professionals – Eve Dubé Oral Abstract Session 2 Room 204 Randomized Evaluation of Live Attenuated vs. Trivalent Inactivated influenza VaccinEs in Schools (RELATIVES) pilot study: Preliminary results from the household surveillance sub-study – Jeff Kwong Cost-benefit analyses of point of care influenza immunization during pregnancy in a Canadian province –Eliana Castillo An assessment of routine rotavirus vaccination coverage among children aged <3 years following the implementation of a publicly-funded rotavirus vaccine program in Québec – Margaret Doll The effect of HPV vaccination on clinical indicators of sexual behaviour in a population-based cohort of adolescent girls in Ontario – Leah Smith Truth in numbers? Validation of immunization registry data for coverage assessment in BC – Samara David

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 37 WEDNESDAY, DECEMBER 3 • 14:30 - 16:00

Practice Room 215 Practical tools for immunizers This session will provide an overview of three important tools for immunizers: • The Canadian Immunization Guide, an important information resource for several decades, has recently undergone extensive revisions and is now available in an electronic format. The Guide will be kept up to date as new NACI recommendations, statements and updates are released and stakeholders can receive automated notifications through a subscription. • Since its debut in 1996, Your Child’s Best Shot: A Parent’s Guide to Vaccination has been the premier reference for Canadian parents on immunization. A fourth edition will be released at the conference. • ImmunizeCA is a free smart phone app that helps parents store and manage their families’ vaccination records, access provincial/ territorial vaccination schedules, and find timely, accurate information on the benefits of vaccination. The mobile app also provides local outbreak alert notifications and resources regarding vaccinations for children, adults and travellers. Learning Objectives: • Review the new features of the Canadian Immunization Guide, including web-only access, the way the content will be kept current and up to date and the subscribe feature for automated updates. • Describe how health care professionals can use the guidebook Your Child’s Best Shot in their encounters with parents and how it will aid parents in decision-making about immunization. • Demonstrate current and upcoming functions within the ImmunizeCA app and how the app benefits Canadians as well as public health. Speakers: Robert Lerch, Manager, NACI Secretariat, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada Dorothy Moore, Associate Infection Control Physician, Infectious Diseases, Montreal Children’s Hospital, McGill University Health Centre Kumanan Wilson, Senior Scientist, Clinical Epidemiology, Ottawa Hospital Research Institute & Professor, Department of Epidemiology & Community Medicine, University of Ottawa Session Chairs: Joanne Langley, Professor of Pediatrics, Faculty of Medicine, Dalhousie University

16:00 – 17:30 Canada Hall 2 & 3 (Level 3) NETWORKING RECEPTION Meet fellow attendees from across the country. Sample food and beverage selections as you mingle, network and make lasting connections. National Advisory Committee on Immunization 50th Anniversary The National Advisory Committee on Immunization (NACI) has provided immunization guidance on the use of vaccines in Canada since 1964. Please join us to celebrate the 50th anniversary. • Presented by: Ian Gemmill, Chairperson, National Advisory Committee on Immunization

38 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM We help public health practitioners find, understand and use infectious disease research and evidence.

The field of infectious diseases is constantly changing, so it’s critical that public health professionals have access to the best, most current expertise and evidence. At the National Collaborating Centre for Infectious Diseases, we specialize in forging connections between those who generate and those who use infectious disease public health knowledge.

Working across disciplines, sectors and jurisdictions, NCCID is uniquely situated to facilitate the creation and operation of nccid.ca networks and partnerships. From policy to practice, we’re able to build bridges between those with infectious disease questions, those with answers, and those in a position to act on the evidence.

Learn more about how our Centre can help you protect and promote the health of Canadians at www.nccid.ca. HOST ORGANIZATION

NCCID is one of six National Collaborating Centres for Public Health, funded by the Public Health Agency of Canada. Learn more: www.nccph.ca THURSDAY, DECEMBER 4

CO-DEVELOPED ACCREDITED LEARNING ACTIVITIES 7:00 – 8:30

Managing influenza in the elderly and paediatric population – New interventions for the prevention of seasonal influenza Room 213 Influenza‐related complications (IRC) cause substantial morbidity and mortality every year in Canada, including an average 12,200 hospitalizations and 3,500 deaths due to acute influenza illness, pneumonia, and all‐cause influenza‐ associated mortality. The paediatric and elderly populations are especially vulnerable. Influenza A accounts for the vast majority of influenza illness, with influenza B accounting for only about 17% of all positive laboratory‐confirmed tests for influenza. Influenza vaccination is recommended for every Canadian older than 6 months, unless a direct contraindication to the vaccine exists. There are currently 8 influenza vaccines of 4 types authorized for use and available in Canada. With so many influenza vaccines from which to choose, understanding which vaccine to offer can be a daunting task. This symposium will review the epidemiology of influenza in Canada and discuss the current recommendations whilst reviewing novel clinical data. Learning Objectives: • Identify who should be vaccinated against influenza, and identify high priority patient groups for vaccination. • Describe the influenza vaccination types available in Canada and their relative mechanisms. • Understand the clinical data supporting the safety and tolerability of the MF59 adjuvanted seasonal trivalent various influenza vaccine in these two populations. Speakers: Steven Black, Professor, Department of Pediatrics, University of Cincinnati Dat Tran, Staff Physician, Infectious Diseases, The Hospital for Sick Children & Assistant Professor, Paediatrics, University of Toronto Mark Loeb, Division Director, Infectious Diseases, McMaster University Session Chair: Mark Loeb, Division Director, Infectious Diseases, McMaster University This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Paediatric Society (CPS). The program was co-developed with CPS, the International Centre for Infectious Diseases and Novartis and was planned to achieve scientific integrity, objectivity and balance.

Shingles prevention: Update on current status and emerging risk factors Room 201 The incidence of herpes zoster (HZ) increases dramatically with age, affecting quality of life and health status and may lead to various complications. As baby boomers age, their chances of experiencing HZ increases, thus making the prevention, diagnosis and treatment of HZ of great importance to healthcare professionals. An important question yet to be addressed is whether herpes zoster vaccination programs should be publicly funded. This session will review: burden and epidemiology of HZ and postherpetic neuralgia (PHN), efficacy and safety of the zoster vaccine, emerging data on increased risk for shingles in various patients including those with diabetes, complications related to herpes zoster including ophthalmic zoster and stroke, the cost effectiveness of HZ vaccination and the revised recommendations from NACI and the Canadian Immunization Committee.

40 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM THURSDAY, DECEMBER 4

Learning Objectives: • Describe the burden and epidemiology of herpes zoster (HZ) and post herpetic neuralgia (PHN). • Discuss herpes zoster vaccine efficacy and safety. • Identify patients who are at increased risk for shingles including those with diabetes. • Summarize complications related to herpes zoster including ophthalmic zoster and stroke. Speakers: Fred Aoki, Professor of Medicine, Medical Microbiology and Pharmacology & Therapeutics, College of Medicine, Faculty of Health Sciences, University of Manitoba Marla Shapiro, Associate Professor, Department of Family and Community Medicine, University of Toronto Session Chair: Arielle Goldman Smith, Program Consultant, MIMS Program Project Coordinator, Manitoba Health This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Association of Medical Microbiology and Infectious Disease (AMMI) Canada. The program was co-developed with AMMI Canada and Merck Canada Inc. and was planned to achieve scientific integrity, objectivity and balance.

The many faces and ages of pneumococcal disease: Vaccine prevention update Room 215 Invasive pneumococcal disease affects the young, the old and the multimorbid. Immunization protects these groups and should be a routine in all practices. This program will review the science behind pneumoccal vaccination and will review the indications and practicalities of immunizing different patient groups highlighting clinical differences and similarities. Learning Objectives: • Describe the various risk factors for pneumococcal disease at all ages. • Gain insight into the impact of pneumococcal vaccines, considering the prevalence and virulence of specific Streptococcus pneumoniae serotypes. • Summarize recent pneumococcal vaccine-related NACI statements and schedule updates. Speakers: Shelly A. McNeil, Professor, Department of Medicine and Division of Infectious Diseases, Faculty of Medicine, Dalhousie University Wendy Vaudry, Professor, Department of Paediatrics, University of Alberta, Director of Infectious Diseases, Stollery Children’s Hospital George Zhanel, Professor, Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba Session Chair: Alan Kaplan, Chairperson, Family Physicians Airways Group of Canada This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by the Association of Medical Microbiology and Infectious Disease (AMMI) Canada. The program was co-developed with AMMI Canada, Family Physicians Airways Group of Canada and Pfizer Canada and was planned to achieve scientific integrity, objectivity and balance.

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 41 THURSDAY, DECEMBER 4

9:00 – 10:30 Canada Hall 1 (Level 3) ACKNOWLEDGEMENTS & PLENARY III

Bernard Duval Foundation Vaccinology Student Research Program Bursary

Presented by: • Gaston De Serres, Medical Epidemiologist, Institut national de santé publique du Québec

New Directions and Priorities: National Immunization Strategy Since its launch in 2003, the National Immunization Strategy (NIS) has strengthened federal, provincial, and territorial collaboration on a range of immunization issues; contributed to the protection of Canadians from vaccine-preventable diseases; and helped reduce health care costs across Canada. Recognizing the benefits of national collaboration across a wide spectrum of immunization issues – from purchasing to reporting and researching to evaluating and beyond -- the NIS renewal is charting a course for further improvements and collaboration. This presentation will highlight key areas of the 2012/13 NIS review and discuss the approach for revitalizing this important initiative. Presented by: • Judith Bossé, Assistant Deputy Minister, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada • Horacio Arruda, National Director of Public Health, Ministre de la Santé et des Services sociaux, Quebec Dr. John Waters Memorial Lecture The John Waters Memorial Award was initiated in 2002 in recognition of his outstanding leadership in support of immunization programs and policy. The purpose of the Dr. John Waters Memorial Award is to recognize other outstanding contributors to public health and immunization programs. Presented by: • Bryce Larke, Dr. John Waters Memorial Committee

Barbara Law, 2014 Dr. John Waters Memorial Award Recipient Over a career spanning 35 years, Dr. Law has made numerous contributions through her clinical and academic work - from risk factors for severe RSV infection in premature infants to the epidemiology and costs of varicella infection. She participated in numerous vaccine development trials and was a founding member of IMPACT, which up to today forms the backbone of vaccine safety monitoring and surveillance for paediatric infectious diseases in Canada. Through policy committees, and working groups, Dr Law has helped drive forward the public health agenda in communicable disease control, immunization and vaccine safety. She was the first coordinator of the CAIRE vaccinology course and chaired PHAC’s Professional Education Working Group that developed the Immunization Competencies for Health Professionals. Dr Law has committed her life and career to the science and promotion of child health and public health programmes across Canada, for the benefit of children everywhere.

42 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM THURSDAY, DECEMBER 4

Plenary III: Vaccine safety: Through the looking glasses Vaccine safety, perceived as well as real, is critically important to public confidence in vaccines and immunization. This is a global concern and one that involves a very broad range of stakeholders, each with roles and responsibilities. The evidence that informs vaccine safety has lagged behind that for vaccine immunogenicity, efficacy and effectiveness. However, the pace of knowledge generation has accelerated in recent decades thanks to new methodologies and resources. Many challenges remain. This plenary will look at vaccine safety from a variety of viewpoints in time, space and personal perspective in order to paint a picture of what has gone before, where we stand now and what the future can and should hold. Learning Objectives: • Describe major milestones in the development of vaccine pharmacovigilance. • Explain eight key components of Canada’s current vaccine safety system that together provide a strong base for consumer confidence in immunization. • Compare and contrast stakeholder roles and responsibilities for vaccine safety from local to global settings. • Summarize remaining challenges to realizing an optimum safety system in Canada and evaluate how each might contribute to achieving it over the next five years! Speaker: Barbara Law, Chief, Vaccine Safety, Surveillance and Outbreak Response Division, Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada Session Chair: Bryce Larke, Dr. John Waters Memorial Committee

10:30 – 11:00 Level 2 REFRESHMENT BREAK

CONCURRENT SESSIONS 11:00 – 12:30

Monitoring & Surveillance Room 206 Surveillance: An important driver for public health action This session will focus on the direct link between surveillance and public health action. Discussions will centre on how surveillance findings inform vaccine development, immunization recommendations, targeted research, and other public health interventions such as communications strategies and preliminary investigation following signal detection. Learning Objectives: • Describe the role of passive and active surveillance of routinely collected data in monitoring effectiveness of immunization programs and how these are used to promote and adjust programs. • Discuss the roles of local, provincial and federal surveillance for driving public health action. • Explain the importance of advance planning for securing information about the burden of illness of diseases that are not yet vaccine-preventable and of advanced methods (e.g., record linkage) to inform evaluation of impact. • Describe enhanced methods of surveillance to provide real-time information.

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 43 THURSDAY, DECEMBER 4

Speakers: Monika Naus, Medical Director, Immunization Programs and Vaccine Preventable Diseases, BC Centre for Disease Control Jat Sandhu, Regional Director, Public Health Surveillance, Vancouver Coastal Health Monique St-Laurent, A/ Director, Vaccine and Immunization Program Surveillance Division, Public Health Agency of Canada Session Chair: Monika Naus, Medical Director, Immunization Programs and Vaccine Preventable Diseases, BC Centre for Disease Control

Vaccine Research & Development Room 215 New vaccines for Canada Canada has unique research facilities and infrastructure for the development and evaluation of new vaccines. This session will describe how Canadian researchers are involved in evaluation of a newer class of protein-based meningococcal vaccine and the development of newer vaccines for protection of vulnerable populations. The presentations will highlight the unique collaborative efforts of Canadian researchers from the fields of public health, basic science research and bioprocessing, working together on developmental vaccine work. Learning Objectives: • Discuss the Canadian experience with a new class of protein-based meningococcal vaccine. • Evaluate Haemophilus influenzae serotype a as an emerging cause of serious invasive disease and the opportunity for its control. • Discuss the development of a Respiratory Syncytial Virus vaccine from bench research to bioprocessing. Speakers: Luis Barreto, Special Advisor - Vaccine Program, Better Vaccine High-Risk Population, National Research Council Vladimir Gilca, Quebec Public Health Institute, Laval University James Richards, Program Lead / Director General, Vaccines Program, National Research Council Marina Ulanova, Professor of Immunology, Division of Medical Sciences, Northern Ontario School of Medicine, Lakehead University Sylvia van den Hurk, Program Manager, Viral Pathogenesis & Vaccine Development Program, VIDO-InterVac & Professor, Microbiology and Immunology, College of Medicine, University of Saskatchewan Session Chair: Shalini Desai, Medical Specialist, Vaccine Preventable Diseases, Public Health Agency of Canada

#cic2014 @cic2014cci

44 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM THURSDAY, DECEMBER 4

Policy-making Room 208 Vaccine program evaluation: Methods and considerations for estimating vaccine effectiveness Vaccine efficacy derives from randomized controlled trials while vaccine effectiveness studies in the field are necessary to inform vaccination policy and may bring different information to the policy-making process. This session will describe strategies and considerations for the evaluation of field vaccine effectiveness (VE), and discuss the importance of VE data to evaluate and inform vaccination policy. Learning Objectives: • Explain the importance of VE studies, and how these data can/should inform vaccine policy. • Identify potential opportunities and challenges for the evaluation of vaccine effectiveness. • Describe several basic designs and methodological considerations for estimating vaccine effectiveness. • Identify data and information required to estimate vaccine effectiveness. Speakers: Philippe DeWals, Professor, Department of Social and Preventive Medicine, Laval University; Public Health Specialist, Institut national de santé publique du Québec Margaret Doll, PhD Candidate, Department of Epidemiology, Biostatistics and Occupational Health, McGill University Tim Hilderman, Medical Officer of Health, Interlake Region, Manitoba Health Danuta Skowronski, Epidemiology Lead, Influenza & Emerging Respiratory Pathogens, BC Centre for Disease Control Session Chair: Margaret Doll, PhD Candidate, Department of Epidemiology, Biostatistics and Occupational Health, McGill University

Programs Room 210 Technology and immunization programs This session will focus on presenting the various technologies that support immunization program goals, and discuss the ethical and legal issues associated with these technologies. Learning Objectives: Describe the utility and benefits of technologies for supporting immunization programs. Discuss the relationship between emerging technologies and immunization programs. Explain the social, ethical and legal implications associated with the use of new technologies in immunization programs. Speakers: Katherine Atkinson, Research Coordinator, Ottawa Hospital Research Institute Julie Bettinger, Investigator, Vaccine Evaluation Centre, Child &Family Research Institute & Associate, BC Children’s Hospital & Associate Professor, School of Population and Public Health, Faculty of Medicine, University of British Columbia Tim Caulfield, Professor, Faculty of Law and School of Public Health, University of Alberta & Canada Research Chair in Health Law and Policy Sandra Donatucci, Senior Marketing Advisor, Health and Safety Marketing Unit, Health Canada Session Chair: Lucie Marisa Bucci, Senior Manager, Immunize Canada, Canadian Public Health Association

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 45 THURSDAY, DECEMBER 4

Practice Oral Abstract Session 1 Room 202 Impact of parent-directed education on parental administration of pain treatments for their children during routine infant immunizations: A cluster randomized trial – Anna Taddio Pain mitigation during adult vaccine injections – Kathryn Cull A pre-and post-intervention study measuring the effect of an interactive education initiative on adolescent perceptions of vaccines, vaccine safety and disease risk – Jaymie-lynn Blanchard Influenza vaccination in chronically ill children – Joanna Merckx Understanding the impact of approved but unfunded vaccine status on parental acceptance of a novel meningococcal serogroup B vaccine for infants – William Fisher Oral Abstract Session 2 Room 204 Using healthcare equity audits to improve childhood immunization coverage rates in vulnerable populations – Shovita Padhi No missed opportunities – Kerry Kennedy #Measles: A local public health unit experience with social media during a measles outbreak – Catherine Dickson An Ontario-based study investigating the role of trust in flu vaccination: Implications for addressing declining uptake – Samantha Meyer Reducing vaccine wastage in First Nation communities – Donna Stanley

46 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM THURSDAY, DECEMBER 4

12:30 – 14:30 Canada Hall 1 (Level 3) LUNCH, PLENARY IV & CLOSING CEREMONY

Plenary IV: The future of immunization – shifting paradigms in adult immunization and vaccine development Despite the successes we have seen in pediatric immunizations, there remains more to be done to protect our world against vaccine preventable diseases. This plenary will explore two areas where we have both opportunities and challenges. In the short term, adult immunization coverage is an area where we can and must improve. We will explore the reasons why adult immunizations rates are relatively poor and policy initiatives that can help improve outcomes. For the long term, we are standing at the forefront of new challenges to vaccine research and development. Many of the “low-hanging fruits” in vaccine development have been accomplished and there is greater fear of new vaccine technology, particularly regarding the use of adjuvants. Future vaccine R & D will depend on cooperation between the public and private sector so that the needs of stakeholders can be met. Previously, vaccines were public health goods. This model evolved into the current doctrine where vaccines are profitable and received investment leading to new vaccine R & D. We now enter a new era with significant challenges and we need to evolve, building upon our successes, in order to move forward. Learning Objectives: • Explain the opportunities and challenges of adult vaccination. • Describe the future of vaccine research and development, policies and programs. • Investigate the relationship between the public and private sector, explore challenges and analyze future roles as they relate to vaccine research and development. Speaker: Litjen (L.J.) Tan, Chief Strategy Officer, Immunization Action Coalition Session Chair: Joanne Langley, Professor of Pediatrics, Faculty of Medicine, Dalhousie University

#cic2014 @cic2014cci

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 47 CONFERENCE COMMITTEES

The Conference Organizing Committee provides advice, strategic directions and recommendations for the development of the program.

Gina Charos, Co-Chair Anna Taddio Public Health Agency of Canada The Hospital for Sick Children / University of Toronto Representing the Canadian Pharmacists’ Association Ian Culbert, Co-Chair Canadian Public Health Association David Scheifele, Scientific Co-Chair Scientific Review Committee University of British Columbia David Scheifele, Scientific Co-Chair Representing the Canadian Association for Immunization Research University of British Columbia and Evaluation Joanne Langley, Scientific Co-Chair Joanne Langley, Scientific Co-Chair Dalhousie University Dalhousie University Representing the Canadian Association for Immunization Research Heather Deehan and Evaluation Public Health Agency of Canada Gordean Bjornson Shelley Deeks Canadian Association for Immunization Research and Evaluation Public Health Ontario Lucie Marisa Bucci Jeff Kwong Immunize Canada Institute for Clinical Evaluative Sciences, University of Toronto Andrea Coady First Nations Inuit Health Branch, Health Canada (from October) Marilyn McIvor McIvor Immunization Services Marie Adèle Davis Canadian Paediatric Society Anne Pham-Huy Children’s Hospital of Eastern Ontario Ian Gemmill Kingston, Frontenac and Lennox & Addington Caroline Quach Public Health The Montreal Children’s Hospital / McGill University Representing the National Advisory Committee Chantal Sauvageau on Immunization Institut national de santé publique du Québec Arielle Goldman Smith Kathryn Slater Manitoba Health Capital Health (Halifax) Representing Canadian Nursing Coalition for Immunization Nany Grimard Ouellette Special thanks to the abstract reviewers. Your time, effort and First Nations Inuit Health Branch, Health Canada (until October) expertise helped us to plan an innovative and thought-provoking conference. Althea House Public Health Agency of Canada Babafunso Adenuga Julie Laroche Nathalie Labonté Michael Arget Nicole Le Saux Pfizer Canada Kathryn Banks Y. Anita Li Representing BIOTECanada Julie Bettinger Joanna Merckx Yvette Biggs Francois Milord Gertrude Oliver Margaret Doll Nova Scotia Health and Wellness Michelle Murti Diego Garcia Boniface Mutatina Representing the Council of Chief Medical Dianne Groll Officers of Health Clara Rubincam Lynn Humber Margaret Russell Marc Ouellette Joan Johnston Marina Salvadori Canadian Institutes of Health Research – Institute of Infection and Olayemi Kadri Laura Sauve Immunity Matthieu Kamwa Judith Shindman Mohan Karkada Faye Stark Carolyn Pim Stephanie Kowal Lorraine Telford Ottawa Public Health Deepali Kumar Jessica Tuengel Caroline Quach Po-Po Lam The Montreal Children’s Hospital / McGill University Representing the Association of Medical Microbiology and Infectious Disease Canada

48 CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM FLOOR PLANS

Level 2 – Concurrent Sessions

Level 3 – Plenary & Exhibit Hall

CANADIAN IMMUNIZATION CONFERENCE 2014 • FINAL PROGRAM 49 SPONSORS

The Canadian Immunization Conference recognizes the generous support of the following organizations:

Program Supporter

Platinum Vaccines

Gold

Silver

Bronze

Contributor